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When considering the high clinical heterogeneity of these patients, the risk of IFIs may be remarkably different. Accordingly, if such a risk is not appropriately evaluated, the possibility of an overtreatment in some or an undertreatment in other patients is very likely.
Pagano et al., on behalf of SEIFEM (Sorveglianza Epidemiologica Infezioni Fungine nelle Emopatie Maligne) group, recently published a systematic review of the literature on the risk and incidence of IFIs in the setting of HMs with the aim to consider the main predisposing factors and to suggest practical strategies for prevention and treatment of IFIs. 5 In this review, specific IFI predisposing factors are summarized for each disease class. Depending on the risk of developing IFIs, patients are then divided into three groups: high, intermediate, low-risk group. Briefly, patients with acute myeloid leukemia (AML) or treated with an allogeneic hematopoietic stem cell transplantation (HSCT) have per se an increased risk of IFI. Moreover, some conditions predispose a high risk of IFI, independently of the underlying disease, like neutropenia, relapse/refractory disease, previous history of IFI, salvage therapy and a high dose of steroids.
To facilitate the reading of this analysis and to estimate in each patient the IFI specific risk, we here propose a practical consultation tool composed of a By this approach, each box of the table represents a matching of a specific disease with a specific risk factor. Red boxes, expressing a high risk (HR) of IFI, are used to indicate a reported incidence of IFI above 5%; yellow boxes, expressing an intermediate risk (IR) of IFI, are used to indicate a reported incidence of IFI of 2-5%; green boxes, expressing low risk (LR) of IFI, are used to indicate a reported incidence of IFI minor of 2%. In the case of lacking data, the boxes are white.
Looking at the colored boxes, people can read this table from two different points of view, by focusing on the risk categories or vice versa on the specific HM. In general, the horizontal reading of the table highlights the principal IFI risk factors, regardless of the underlying disease. In particular, red boxes appear to be associated with a long history of HM, with a relapse or refractory disease, a prolong neutropenia, older age, predisposing polymorphisms, pulmonary comorbidities, intense chemotherapy and prolong used of steroids. Some of these risk factors are routinely screened in the clinical practice, others, like predisposing genetic polymorphisms, are used only in experimental setting, but look promising. On the other hand, the vertical reading of the table highlights the disease mostly associated with IFI, in particular, AML and patients undergoing HSCT.
It should be underlined that each disease may present one or more risk factors and that the risk factors may vary during the course of illness and due to the type of treatments. For this reasons, it is important to follow the patient over time, with a dynamic score, evaluating the presence or absence of risk factors, with the aim to start or withdrawn an appropriate antifungal prophylaxis or treatment. In this setting, this table allows a rapid consultation in the clinical practice.
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Neutropenia
Neutropenia at baseline Neutropenia <500/μL for >10gg Legend:  High: incidence > 5%, risk factor that put patient at high risk for IFI, reported in previous studies or risk factor in the setting of HSCT  Intermediate: incidence 2-5%, risk factor known in this setting, but that do not identify a high or low risk for IFI, reported in previous studies  Low: incidence < 2%, risk factor that put patient at low risk for IFI, reported in previous studies Legend:  High: incidence > 5%, risk factor that put patient at high risk for IFI, reported in previous studies or risk factor in the setting of HSCT  Intermediate: incidence 2-5%, risk factor known in this setting, but that do not identify a high or low risk for IFI, reported in previous studies  Low: incidence < 2%, risk factor that put patient at low risk for IFI, reported in previous studies Tyrosine Kinase 
